Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients

<div>Network meta-analysis interval plot of published studies for induction of (a) remission and (b) response in anti-TNF-experienced CD patients. Odds ratios (ORs) with 95% confidence interval (CI) are reported. All the single drugs showed consistent efficacy comparing with placebo while no drug proved to be superior in a statistically significant level to all others in inducing remission. ADA = adalimumab; USTE = ustekinumab; VEDO = vedolizumab; NAT = natalizumab; CERT = certolizumab; PL = placebo.</div>

Gastroenterology Research and Practice

fig4

Figure 4

Figure 4: Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients 

Figure 4 | Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn’s Disease Patients 